CL King tells investors in a research note that Medtronic’s termination of its agreement to acquire EOFlow doesn’t change its view and continues to believe the risk/reward profile is favorable, given Medtronic’s valuation. The firm made no change to its Buy rating or $102 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDT:
- Robotics Stocks: Bot is Man’s Best Friend
- Needham medtech analysts hold analyst/industry conference call
- AtriCure says ‘welcomes’ competition from Medtronic
- Medtronic launch could create an overhang on AtriCure, says Needham
- Medtronic launches Penditure Left Atrial Appendage Exclusion System in U.S.